Ind-Swift Laboratories Share Price

Ind-Swift Laboratories Investment Rating

• Master Rating:

• Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,143.67 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 1% needs improvement, ROE of -0% is poor and needs improvement. The company has a high debt to equity of 210%, which can be a reason to worry. The stock from a technical standpoint is trading close to its 200DMA and around 10% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 42 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.